hATTR-PN

Amvuttra (vutrisiran) safely and effectively eases symptoms, reduces disability, and improves quality of life in East Asian adults with hereditary transthyretin amyloidosis with polyneuropathy…

Use of the approved therapy Wainua (eplontersen) effectively slows disease progression and improves quality of life among adults with hereditary transthyretin amyloidosis with…

A rare mutation in the TTR gene — mutations in which are the cause of hereditary transthyretin amyloidosis (hATTR) — resulted in early, progressive neurological…

A blood test commonly used to help diagnose Alzheimer’s disease may also identify people with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), characterized by damage…

Six months of treatment with Amvuttra (vutrisiran) appears to maintain or slightly improve clinical status and quality of life among adults with hereditary…

Hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) was a common clinical manifestation among people carrying a mutation in the TTR gene called p.Ala117Ser, according to…

Homes and landmarks across the U.S. and other countries will once again light up in red throughout March for Amyloidosis Awareness Month as the…

An easily accessible diagnostic test called pain-related evoked potentials with concentric electrodes (PrEP-CE) may help detect the onset of hereditary transthyretin amyloidosis with polyneuropathy…

Overactivation of Rac1, a protein that regulates components of a cell’s skeleton, may drive early nerve damage in hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN),…

Minimally invasive skin biopsies may be used to diagnose transthyretin amyloidosis and guide treatment in people with the rare progressive disease, according to the findings…